Boniva (ibandronate), a new bisphosphonate for osteoporosis

December 2004

We're getting questions about Boniva (ibandronate), a new bisphosphonate for osteoporosis.

It'll be the first one approved for dosing once a MONTH.

Bisphosphonates are good candidates for intermittent dosing. They can remain active in the bone for several weeks or longer.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Community and hospital pharmacies will share info from patient profiles when patients are admitted and discharged
Men's Health statins might decrease libido or cause erectile dysfunction
Osteoporosis Reps will tout new evidence that Fosamax increases bone density better than Actonel
Osteoporosis Boniva (ibandronate), a new bisphosphonate for osteoporosis
Osteoporosis Is it important to take magnesium along with calcium?
Cardiology whether ACE inhibitors are beneficial for patients with STABLE coronary artery disease
Gastroenterology gastric acid-suppressing drugs increasing the risk of pneumonia
Gastroenterology Reps will tout Zegerid as the first IMMEDIATE-release omeprazole
Kidney Disease Fosrenol will be a new phosphate binder for dialysis patients
NATURAL alternatives to Vioxx
Vitamins & Minerals vitamin E supplements might actually INCREASE mortality
New warnings are raising controversy about the use of antidepressants
new push to use some of the newer antiepileptics
Infectious Diseases it might be possible to stretch the existing supply of injectable flu vaccine
whether atenolol should be used for hypertension
Practice End of year is a good time to reflect on trustworthy drug information that is relevant to practice.